Allakos Inc. (NasdaqGM: ALLK)
Health Care · Biotechnology · US
$—
— today · — 1Y
Allakos Inc. (NasdaqGM: ALLK) operates in the Biotechnology industry within the Health Care sector.
Tweenvest scores Allakos Inc. across four factors: quality 26/100. Its strongest factor is quality.
ALLK price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.79
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 131
- Next earnings
- —
About Allakos Inc.
Allakos Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapeutic agents. These treatments are designed to target specific immunomodulatory receptors on immune effector cells, addressing a spectrum of allergic, inflammatory, and proliferative conditions. The company's flagship investigational product is lirentelimab (AK002), a monoclonal antibody. This compound is currently undergoing a pivotal Phase III clinical trial for eosinophilic gastritis and/or duodenitis. It is also being evaluated in a Phase II/III study for eosinophilic esophagitis, and a Phase II trial for atopic dermatitis and chronic spontaneous urticaria. Furthermore, Allakos is exploring lirentelimab (AK002) for potential use in mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. In parallel, their pipeline includes AK006, another candidate being developed to tackle various allergic and inflammatory diseases. Established in 2012, Allakos Inc. operates from its headquarters located in Redwood City, California.
- ISIN
- US01671P1003
- Founded
- 2012
- Listed since
- Jul 19, 2018
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.95 | -0.00% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.21 | +0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.27 | +0.10% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.98 | -0.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $824.97 | -1.09% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $138.15 | -4.77% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.